Patent · US Active

Monovalent ligand of the FcαRI receptor as an anti-inflammatory agent

US7892538B2 · kind B2 · utility

0Cited by

1References

14Claims

0Family size

Assignee

Institut National de la Sante et de la Recherche Medicale (INSERM) · FR

Inventors

Renato Monteiro · Montrouge, FR
Benoît Pasquier · Cholet, FR
Ulrich Blank · Sartrouville, FR
Marc Benhamou · Paris, FR
Pierre Launay · Paris, FR
Marina Pretolani · Paris, FR

Key dates

Filing date	Mar 4, 2005
Grant date	Feb 22, 2011
Priority date	—
Expiry date	Apr 11, 2027

Classification

Technology area (CPC Y)Emerging Cross-Sectional Technologies
CPC primaryY10S424/809
WIPO fieldPharmaceuticals
WIPO sectorChemistry

Abstract

The invention relates to the use of a monovalent antibody fragment directed against the EC2 domain of the FcαRI receptor for the treatment of inflammatory diseases.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.